Bee Venom Allergy: Shots vs Drops vs Pills — An Honest Treatment Route Review

No. Sublingual drops (SLIT) for bee venom allergy are investigational — not FDA-approved and not standard of care. The only published RCT of sublingual honeybee venom (Severino MG et al., JACI 2008;122:44–48) demonstrated reduced large-local-reaction size compared with placebo but did not validate protection against systemic reactions or anaphylaxis. Subcutaneous venom immunotherapy (VIT, shots) remains the only proven life-saving treatment, with 91 to 96 percent protection for vespid venom and 75 to 85 percent for honeybee venom. Sublingual drops prescribed for environmental allergies (pollen, dust mite, mold, pet dander) contain no venom and cannot treat venom allergy.

No. At-home sublingual immunotherapy services for environmental allergens — pollen, dust mite, mold, and pet dander — do not prescribe venom immunotherapy (VIT). Venom immunotherapy requires subcutaneous injection during in-clinic build-up visits because of anaphylaxis risk during the dose-escalation phase, and this cannot safely be done remotely or at home. Sublingual drop products are formulated for inhalant allergens, not for Hymenoptera venom proteins. Patients who have had systemic sting reactions must be referred to a board-certified allergist for in-clinic venom skin testing and VIT. Any coexisting inhalant allergies — dust mite asthma, pollen rhinitis, mold sensitivity — are separate conditions that can be addressed separately from venom allergy and require their own evaluation.

No FDA-approved oral venom tablet or pill exists for bee venom allergy. Oral tolerance to Hymenoptera venom proteins has not been established in clinical trials. This is in contrast to certain food allergens (peanut, milk, egg) where oral immunotherapy is under active development and partially approved. Oral antihistamines — cetirizine, loratadine, fexofenadine, diphenhydramine — reduce itch and mild urticaria but do not prevent anaphylaxis and are not substitutes for epinephrine or VIT. Taking an antihistamine before potential sting exposure is not a medically recognized prevention strategy.

Venom immunotherapy (VIT) has two phases. The build-up phase escalates from very low to maintenance dose (100 micrograms, equivalent to approximately 2 honeybee stings or 5 yellowjacket stings of venom). Conventional build-up takes about 3 months of weekly injections; rush protocols condense build-up to 2 to 3 days in a clinic; cluster protocols take 4 to 8 weeks with multiple same-day injections. Once maintenance is reached, monthly injections continue for 3 to 5 years for most patients. Patients with mastocytosis, near-fatal prior reactions, or persistently elevated tryptase continue VIT lifelong. Most patients carry epinephrine throughout VIT and for some time after stopping.

Venom immunotherapy is highly effective for most patients. Vespid venom (yellowjacket, wasp, hornet) achieves 91 to 96 percent protection — meaning that after completing VIT, 91 to 96 percent of patients experience no more than a normal local reaction if re-stung. Honeybee venom achieves 75 to 85 percent protection — a somewhat lower efficacy that reflects immunological differences between honeybee and vespid allergens and the underrepresentation of Api m 10 in older therapeutic extracts. Dhami S et al. (Allergy 2017;72:342–365) reported OR 0.08 for subsequent severe systemic reactions in a meta-analysis of VIT studies — a 92 percent reduction in the odds of severe anaphylaxis.

SCIT (subcutaneous immunotherapy) — injections given under the skin at an allergist's office — is the established route for venom immunotherapy and the only validated life-saving treatment. SLIT (sublingual immunotherapy) — drops or tablets placed under the tongue — is the approved route for environmental inhalant allergens in many countries, including the US (certain grass and ragweed tablets). For venom specifically, SLIT is investigational. The Severino 2008 RCT studied sublingual honeybee venom and showed reduced local reactions but no validated systemic protection. SLIT for environmental allergens (pollen, dust mite, mold, pet dander) is a different product for a different indication — it does not contain venom.

Bee venom therapy (apitherapy) is the intentional application of bee stings or crude bee venom products for arthritis, multiple sclerosis, or other conditions — it is not an allergy treatment and is not the same as VIT. Apitherapy is itself a documented cause of anaphylaxis: Park JH et al. (PLoS One 2015;10:e0126971) documented fatal cases associated with bee venom therapy. Venom immunotherapy (VIT) uses standardized, manufactured aqueous venom extracts administered in calibrated doses with emergency equipment available — it is a rigorously controlled medical procedure, not an alternative therapy. Anyone with known venom allergy who undergoes apitherapy is placing themselves at significant, unmitigated anaphylaxis risk.

Most patients do not need lifelong VIT. The standard recommendation is 3 to 5 years of maintenance VIT, after which most patients achieve durable protection that persists even after stopping. Long-term follow-up studies show that approximately 80 percent of patients who complete 3 to 5 years of VIT remain protected for at least 5 more years. However, lifelong VIT is recommended for patients with mastocytosis or elevated baseline serum tryptase, patients who experienced a near-fatal anaphylaxis, and patients who have had severe systemic reactions during VIT itself. Beekeeper and other high-exposure patients may also choose to continue VIT to maintain maximal protection given their occupational sting risk.

Do not stop ACE inhibitors or beta-blockers without consulting your prescribing physician. The role of these medications in venom-allergy severity is genuinely contested. Rueff F et al. (JACI 2009) identified ACE inhibitor use as a predictor of more severe anaphylaxis in a study of 962 Hymenoptera-allergic patients. However, Sturm GJ et al. (Allergy 2021;76:2166–2176) found no independent effect of ACE inhibitors or beta-blockers on anaphylaxis severity after adjusting for age and cardiovascular comorbidities. The 2023 Anaphylaxis Practice Parameter Update recommends presenting both perspectives and individualized decision-making — not blanket discontinuation. Stopping a beta-blocker or ACE inhibitor for cardiovascular disease carries its own significant risk.

Bee (honeybee) and vespid (yellowjacket, wasp, hornet) venoms have distinct protein compositions with low cross-reactivity. Honeybee venom is dominated by Api m 1 phospholipase A2 (57 to 97 percent sensitization) and Api m 4 melittin. Yellowjacket venom is dominated by Ves v 1 phospholipase A1 and Ves v 5 antigen 5. Vespid venoms cross-react strongly among themselves — yellowjacket, wasp (Polistes), and hornet share antigen-5 proteins. Bee and vespid venoms cross-react poorly. Component-specific IgE testing (Api m 1, Ves v 1, Ves v 5) distinguishes genuine double sensitization from cross-reactive carbohydrate determinant (CCD) positivity, which determines whether VIT must cover both bee and vespid or only one. VIT efficacy is higher for vespid (91 to 96 percent) than for honeybee (75 to 85 percent).